Drug Information

Drug (ID: DG01388) and It's Reported Resistant Information

• Name: Ipilimumab
• Indication:
  In total 1 Indication(s)
  Melanoma [ICD-11: 2C30]; Approved; [1]
• Target: Cytotoxic T-lymphocyte protein 4 (CTLA-4); CTLA4_HUMAN; [1]
• TTD Drug ID: D07BVI

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Signal transducer activator transcription 3 (STAT3) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Extensive-disease small-cell lung cancer [ICD-11: 2C25.Z]
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Drug Resistance: FoundationOne CDx assay
• Mechanism Description: Overcoming acquired resistance to chemotherapy treatments through suppression of STAT3, Selective chemotherapy treatments and diagnostic methods related thereto, DR4 modulation and its implications in EGFR-target cancer therapy. Maintenance therapy with nivolumab plus ipilimumab did not prolong OS for patients with ED-SCLC who did not progress on first-line chemotherapy.

References

• Ref 1: Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 .J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. 10.1200/JCO.20.02212